Jeffrey Bockman

Jeffrey Bockman

Company: Lumanity

Job title: Executive Vice President of Commercial BioConsulting & Head of Oncology

Seminars:

Is there a Single “Best” Platform or will it be “Fit to Purpose”? 10:00 am

Analysing the advantages, disadvantages and comparisons of the DNA, Peptide, RNA, and Virus-based and other novel vaccine platforms Harmonisation of clinical outcomes and immune correlates Considering if we can we get better at predictive animal models? Questioning what other signals we need to provide to the immune system, either built into the vaccine or given…Read more

day: Day Two

Is there a Single “Best” Platform or will it be “Fit to Purpose”? 2:00 pm

Analysing the advantages, disadvantages and comparisons of the DNA, Peptide, RNA, and Virus-based and other novel vaccine platforms Harmonisation of clinical outcomes and imune correlates Considering if we can we get better at predictive animal models? Questioning what other signals we need to provide to the immune system, either built into the vaccine or given…Read more

day: Pre-Conference Focus Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.